Caffeine, cannabis and cocaine: From automedication to 'automutilation' in patients with ADHD;Cafeïne, cannabis en cocaïne: Van automedicatie tot 'automutilatie' bij volwassenen met aandachtstekortstoornis met hyperactiviteit (ADHD)

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 52, 2004, Pages 2573-2576

  Rodrigues Pereira, R ^a,b   Van De Wetering, B J M ^a,c  

^a Medisch Centrum Rijnmond Zuid   (Netherlands)

^b Delta Psychiatrisch Ziekenhuis   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CANNABIS; COCAINE; DOPAMINE RECEPTOR AFFECTING AGENT; METHYLPHENIDATE;

ADDICTION; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BEHAVIOR; CASE REPORT; CIGARETTE SMOKING; COFFEE; FEMALE; HUMAN; MALE; MENTAL PERFORMANCE; OUTPATIENT DEPARTMENT; SLEEP INDUCTION;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; METHYLPHENIDATE; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 10944225866     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Weisfelt M, Schrier AC, Leeuw MC de. Druk gedrag bij volwassenen; mogelijk aandachtstekort-hyperactiviteitstoornis (ADHD). Ned Tijdschr Geneeskd 2001;145:1481-4.
2. Buitelaar JK, Kooij JJS. Aandachtstekort-hyperactiviteitstoornis (ADHD); achtergronden, diagnostiek en behandeling. Ned Tijdschr Geneeskd 2000;144:1716-23.
3. Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry 1998;39:65-99.
4. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzius AC, Dickstein DP, et al. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996;53:607-16.
5. Sowell ER, Thompson PM, Welcome SE, Henkenius AL, Toga AW, Peterson BS. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 2003;362:1699-707.
6. Morgan D, Grant KA, Gage HD, Mach RH, Kaplan JR, Prioleau O, et al. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci 2002;5:169-74.
7. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
8. Schonewille WJ. Chronische dagelijkse hoofdpijn door overmatig cafeïnegebruik. Ned Tijdschr Geneeskd 2002;146:1861-3.
9. Huestis RD, Arnold RE, Smeltzer DJ. Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison. Am J Psychiatry 1975;132:868-70.
10. Dalby TJ. Will population decreases in caffeine consumption unveil attention deficit disorders in adults? Med Hypotheses 1985;18: 163-7.
11. Pomerleau CS, Downey KK, Snedecor SM, Mehringer AM, Marks JL, Pomerleau OF. Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD, and adult ADHD symptomatology. Addict Behav 2003;28:1149-57.
12. Lissoni P, Resentini M, Mauri R, Esposti D, Esposti G, Rossi D, et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res 1986;18:77-8.
13. Smits MG, Stel HF van, Heijden K van der, Meijer AM, Coenen AM, Kerkhof GA. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2003; 42:1286-93.
14. Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000;61:244-51.
15. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind placebo-controlled trial of methylphenidate phenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10:286-94.